{
    "clinical_study": {
        "@rank": "119275", 
        "arm_group": {
            "arm_group_label": "Live Attenuated Varicella Vaccine", 
            "arm_group_type": "Experimental", 
            "description": "use the left arm flank deltoid muscle adheres to stick cohere place the skin after 75% ethyl alcohol disinfection the hypodermic injection"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to observe the occurrence of adverse events, seroconversion\n      rate and geometric mean titres(GMTs) of 2 doses of live attenuated varicella vaccine."
        }, 
        "brief_title": "Immunogenicity and Safety Study of 2 Doses of Live Attenuated Varicella Vaccine", 
        "completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "condition": "Chickenpox", 
        "condition_browse": {
            "mesh_term": "Chickenpox"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Parent/legal acceptable representative is willing and able to understand the protocol\n             requirements and provide informed consent\n\n          -  Participant is aged \u2265 1 year to \u2264 3 years\n\n          -  Participant without preventive inoculation of varicella vaccine and previous history\n             of chickenpox and zoster\n\n          -  Subject and parent/guardian able to attend all scheduled visits and comply with all\n             trial procedures\n\n          -  Body temperature \u2264 37.5\u2103\n\n        Exclusion Criteria:\n\n          -  Known allergy to any constituent of the vaccine\n\n          -  Known acute illness, severe chronic disease, acute exacerbation of chronic disease\n             and fever\n\n          -  Known or suspected impairment of immunologic function, or receipt of\n             immunosuppressive therapy or immunoglobulin since birth\n\n          -  Reported the history of allergies, convulsions, epilepsy, mental illness and brain\n             disease and clear serious systemic reaction\n\n          -  Failed to the Expanded Programme on Immunization(EPI)\n\n          -  Receipt of any vaccine in the 4 weeks preceding the trial vaccination\n\n          -  Plan to receive any vaccine in the 4 weeks following the trial vaccination\n\n          -  Known bleeding disorder\n\n          -  Receipt of whole blood, blood plasma or immunoglobulin in the 5 months preceding the\n             trial vaccination\n\n          -  Reported the history of acute illness had need systemic antibiotics or anti-viral\n             treatment of infections in the 7 days preceding the trial vaccination\n\n          -  An acute illness with or without fever (temperature \u2265 38.0\u2103) in the 3 days preceding\n             enrollment in the trial\n\n          -  Participation in any other interventional clinical trial\n\n          -  Any condition which, in the opinion of the investigator, would pose a health risk to\n             the subject or interfere with the vaccine"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "3 Years", 
            "minimum_age": "1 Year"
        }, 
        "enrollment": {
            "#text": "368", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "March 4, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01817270", 
            "org_study_id": "NCT02038506"
        }, 
        "intervention": {
            "arm_group_label": "Live Attenuated Varicella Vaccine", 
            "intervention_name": "Live Attenuated Varicella Vaccine", 
            "intervention_type": "Biological"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "October 14, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Yunfu", 
                    "country": "China", 
                    "state": "Guangdong"
                }, 
                "name": "Xinxing Center for Disease Control and Prevention"
            }
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Study to Evaluate the Immunogenicity and Safety of 2 Doses of Live Attenuated Varicella Vaccine", 
        "overall_official": {
            "affiliation": "Guangdong Center for Disease Control and Prevention", 
            "last_name": "Huizhen Zheng, Master", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Seroconversion rate and GMTs for live attenuated varicella vaccine", 
            "safety_issue": "No", 
            "time_frame": "35-42 days after the first and second doses"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01817270"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Occurrence of adverse events", 
            "safety_issue": "Yes", 
            "time_frame": "within 30 days after each vaccination"
        }, 
        "source": "Changchun Keygen Biological Products Co., Ltd.", 
        "sponsors": {
            "collaborator": {
                "agency": "Guangdong Provincial Institute of Biological Products And Materia Medica", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Changchun Keygen Biological Products Co., Ltd.", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}